Bezlotoxumab Reduces Odds of Recurrent C Difficile for Organ Transplant Recipients

Loading
32550login-checkBezlotoxumab Reduces Odds of Recurrent C Difficile for Organ Transplant Recipients

New research shows bezlotoxumab is effective at reducing the risk of recurrent Clostridioides difficile infections (CDI) at the 90 day mark in a cohort of patients recently receiving solid-organ transplantation.

A team, led by Tanner M. Johnson, Department of Pharmacy, UCHealth University of Colorado Hospital, compared recurrent C difficile infection rates in solid-organ and hematopoietic-cell transplant recipients.

Read more, here.

325500login-checkBezlotoxumab Reduces Odds of Recurrent C Difficile for Organ Transplant Recipients
Loading

Leave a Reply